TY - JOUR T1 - Anti-annexin A5 antibodies in women with spontaneous pregnancy loss JO - Medicina Clínica T2 - AU - Alijotas-Reig,Jaume AU - Ferrer-Oliveras,Raquel AU - Rodrigo-Anoro,María José AU - Farran-Codina,Inmaculada AU - Llurba-Olivé,Elisa AU - Vilardell-Tarres,Miquel AU - Casellas-Caro,Manel SN - 00257753 M3 - 10.1016/j.medcli.2009.09.040 DO - 10.1016/j.medcli.2009.09.040 UR - https://www.elsevier.es/es-revista-medicina-clinica-2-articulo-anti-annexin-a5-antibodies-in-women-S0025775309014560 AB - Background and ObjectiveThe aim was to evaluate the role of anti-annexin A5 (anti-ANXA5) antibodies as risk factor for recurrent miscarriage (RM) and unexplained fetal loss (UFL). Patients and methodsRetrospective, cohort study. Setting: Vall d’Hebron University Hospital. Subjects: 122 women, in two groups: Study group: 54 women with RM/UFL and control group: 68 pregnant without RM/UFL. Intervention: Antiphospholipid, mainly anti-ANXA5 antibody analysis. Comparison of all antiphospholipid antibodies between groups. ResultsAntiphospholipid antibody (aPL) prevalence in the study group was 10/54 (14.8%) and 5/68 (7.3%) in control group (p=0.09). In the RM subgroup, it was 3/25 and 9/34 in UFL versus 5/68 in controls (p=0.013). Lupus anticoagulant (LA) was present in 4 cases, all belonging to the study group (p=0.011). Four out of 34 women with UFL were positive for anticardiolipin antibodies-IgG (IgG-aCL) versus 1/68 in controls (p=0.041). In RM subgroup, anti-ANXA5 antibodies were positive in 2/25 versus 3/68 in controls, and in UFL subgroup, 3/34 versus 3/68 cases (p=1.000). ConclusionAccording to our results, anti-ANXA5 antibodies should not be considered as a risk factor for RM/UFL. ER -